What drugs does Gilead own?
Gilead Sciences owns and commercializes a robust portfolio of breakthrough antiviral, oncology, and inflammatory therapeutics that have transformed global healthcare. Its most famous owned assets include revolutionary HIV treatments such as Biktarvy, Descovy, Truvada, Genvoya, and Biktarvy, alongside hepatitis C curative blockbusters Harvoni and Epclusa. Furthermore, Gilead owns Veklury for treating COVID-19 and expanded its oncology portfolio through acquisitions to include Trodelvy, an antibody-drug conjugate prescribed for metastatic triple-negative breast cancer and urothelial carcinoma.
Related FAQs
Assessing Axcelis Technologies stock as an investment involves weighing its strong positioning in the semiconductor supply chain against cyclical industry downturns and valuation shifts.
The share price of Arcellx, Inc. (listed on the NASDAQ global market under the ticker symbol ACLX) is approximately 115.07 USD.
Yes, First Security Bank currently operates as a division of Glacier Bank, which is a key component of the regional bank holding company Glacier Bancorp, Inc.
Arcellx completed its definitive merger agreement with Gilead Sciences, under which Gilead acquired the company for a substantial cash price per share plus a contingent value right.
Gilead Sciences has significantly expanded its antiviral, oncology, and cell therapy pipeline through major strategic corporate acquisitions.
The regenerative medicine and stem cell therapeutics sector features innovative biotechnology enterprises pioneering advanced clinical treatments for degenerative diseases, autoimmune disorders, and trauma recovery.
Under the definitive agreement and plan of merger between Gilead Sciences and Arcellx Inc (ACLX), Gilead acquired Arcellx through a structured two-step transaction consisting of a cash tender offer followed by a merger.
Determining whether Arcellx (ACLX) represents a favorable buy recommendation requires examining its clinical-stage biotechnology pipeline, particularly its innovative cell therapies targeting cancer and severe autoimmune conditions.
Identifying premier equities within the regenerative medicine space involves targeting biotechnology pioneers with advanced late-stage clinical pipelines and strong patent portfolios.
Arcellx, Inc. is a clinical-stage biotechnology company dedicated to reimagining cell therapy through the development of innovative immunotherapies targeting cancer and other incurable diseases.
The acronym ACLX serves as the NASDAQ stock ticker symbol for Arcellx, Inc.